Very sharp question! It depends on your definition of "better". If your definition is based on strict adherence to a standardized and documented validation process, you will conclude that cGMP products are better than non-GMP products.

Of course, there's another aspect to your definition of "better": analytical testing. For example, the number of tests, impurity control, test result tolerances and test methods. ACS reagent products do not have requirements for how the product is manufactured, but there are requirements for the analytical method and product results. Unlike ACS reagent chemistries, cGMP-produced peptides may not have items to be tested (excluding the United States Pharmacopeia or the European Pharmacopoeia), as long as the manufacturer and its partners define the processes, attributes, and results that are important to the partners. cGMP peptide products must be manufactured using a documented and validated process. Any deviations in the process may result in the product being considered adulterated and may be rejected, even if the product meets all analytical specifications.

Ultimately, the conclusion is:

If your definition of "better" prioritizes the highest degree of manufacturing process reliability, risk control, and comprehensive regulatory compliance (especially in the pharmaceutical field), then cGMP peptides are undeniably the "better" choice. They ensure that the product is manufactured in a controlled and predictable environment.

However, if your definition of "better" focuses more on the specific analytical purity and impurity content of the final product (e.g., a high purity requirement without strictly mandating the manufacturing process itself), then you'll need to carefully review the Certificate of Analysis (CoA) provided for the product. Compare it with non-cGMP suppliers who nonetheless maintain rigorous analytical testing standards. Some non-cGMP manufacturers may also invest heavily in extensive analytical testing.